Skip to main content
Back
| 24.10.2024
Topadur Pharma AG announces CEO change

The Board of Directors of Topadur Pharma AG announces that Pascal Brenneisen will leave his position as CEO to pursue new professional challenges.

Since taking on the role in 2023, Mr. Brenneisen has made significant progress in guiding the company toward a future-oriented strategy and fostering a cultural change in preparation for an IPO. The Board of Directors expresses its appreciation to Mr. Brenneisen for his dedication to the company.

His vision has laid a good foundation for the company’s growth and success. As active shareholder he will still stay connected to Topadur Pharma AG.

Chairman of the Board, Dr. Reto Naef, will take over direct corporate leadership of the company on an interim basis until a successor is appointed.

The Board wishes Mr. Brenneisen all the best for his future.

‍

‍

Contact

Yoshita Bhide
Communications
+41 44 755 44 66
yoshita.bhide@topadur.com

Send a message

DISCLAIMER
This communication does not constitute an offer or invitation to subscribe for or purchase any securities of TOPADUR PHARMA AG. This publication may contain certain forward-looking statements and assessments or intentions concerning the company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly not in connection with any contract or investment decision. The company disclaims any obligation to update these forward-looking statements, assessments or intentions.